TR200806646A2 - Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar - Google Patents
Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlarInfo
- Publication number
- TR200806646A2 TR200806646A2 TR2008/06646A TR200806646A TR200806646A2 TR 200806646 A2 TR200806646 A2 TR 200806646A2 TR 2008/06646 A TR2008/06646 A TR 2008/06646A TR 200806646 A TR200806646 A TR 200806646A TR 200806646 A2 TR200806646 A2 TR 200806646A2
- Authority
- TR
- Turkey
- Prior art keywords
- levodopa
- entacapone
- pharmaceutical combinations
- carbidoba
- combinations including
- Prior art date
Links
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 title abstract 3
- 229960003337 entacapone Drugs 0.000 title abstract 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004502 levodopa Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2008/06646A TR200806646A2 (tr) | 2008-09-03 | 2008-09-03 | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| PCT/TR2009/000112 WO2010027340A1 (fr) | 2008-09-03 | 2009-09-03 | Compositions pharmaceutiques d'entacapone, de levodopa et de carbidoba |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2008/06646A TR200806646A2 (tr) | 2008-09-03 | 2008-09-03 | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200806646A2 true TR200806646A2 (tr) | 2009-06-22 |
Family
ID=41314610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2008/06646A TR200806646A2 (tr) | 2008-09-03 | 2008-09-03 | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR200806646A2 (fr) |
| WO (1) | WO2010027340A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107653A2 (fr) * | 2010-03-04 | 2011-09-09 | Orion Corporation | Méthode de traitement de la maladie de parkinson |
| TR201204839A2 (tr) | 2012-04-25 | 2012-12-21 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu. |
| JP6472391B2 (ja) * | 2013-03-13 | 2019-02-20 | ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ | パーキンソン病の治療方法 |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20060173074A1 (en) * | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
| US20060222703A1 (en) * | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| KR101617990B1 (ko) * | 2005-06-08 | 2016-05-03 | 오리온 코포레이션 | 경구 용량 형태 |
| US8741342B2 (en) * | 2006-10-30 | 2014-06-03 | Wockhardt Research Centre | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa |
| EP2252284B1 (fr) * | 2008-02-06 | 2011-05-25 | Wockhardt Research Centre | Compositions pharmaceutiques d'entacapone, de lévodopa et de carbidopa à biodisponibilité améliorée |
-
2008
- 2008-09-03 TR TR2008/06646A patent/TR200806646A2/xx unknown
-
2009
- 2009-09-03 WO PCT/TR2009/000112 patent/WO2010027340A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010027340A1 (fr) | 2010-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| NO20074823L (no) | Rasagilin-formuleringer med forbedret innholdsensartethet | |
| EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| TN2011000209A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| CY1118374T1 (el) | ΣΥΝ-ΚΡΥΣΤΑΛΛΟΙ ΤΡΑΜΑΔΟΛΗΣ KAI NSAIDs | |
| EP2582676A4 (fr) | Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA200900044A1 (ru) | Замещенные производные 1,3-дифенилпропана, получение и их применение | |
| TW200730515A (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
| WO2007095050A3 (fr) | N-hydroxyguanidines comme modulateurs de l'indolamine 2,3-dioxygénase | |
| EA201370208A1 (ru) | Формы рифаксимина и их применение | |
| BRPI0516483A (pt) | preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| UA98961C2 (uk) | Похідні піразинону та їх застосування у лікуванні легеневих захворювань | |
| MY142067A (en) | Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease | |
| MX2009011364A (es) | Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2-il) y n-(5-heteroarilcroman-3-il)carboxamida para el tratamiento del dolor. | |
| ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
| WO2007100366A3 (fr) | Modulateurs allostériques positifs du récepteur de la quinolone m1 | |
| BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
| TR200806646A2 (tr) | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar | |
| BRPI0508051A (pt) | derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes |